Effects of triptolide herb on the progression of Alzheimer's disease preclinical models: a systematic review
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Triptolide (Tri) shows significant neuroprotective effects in Alzheimer's disease (AD) preclinical models by reducing amyloid-beta and inflammation. Further research is needed to explore its clinical potential for AD treatment.
Area Of Science
- Neuroscience
- Pharmacology
- Biochemistry
Background
- Alzheimer's disease (AD) is a leading cause of dementia with limited disease-modifying treatments.
- Triptolide (Tri), derived from <i>Tripterygium wilfordii</i>, exhibits anti-inflammatory, antioxidant, and neuroprotective properties.
- Existing AD therapies primarily manage symptoms, highlighting the need for treatments targeting underlying pathology.
Purpose Of The Study
- To systematically evaluate and synthesize preclinical evidence on Triptolide's neuroprotective effects in Alzheimer's disease models.
- To assess Tri's impact on key AD pathological hallmarks including amyloid-beta accumulation, neuroinflammation, oxidative stress, synaptic dysfunction, autophagy, and apoptosis.
- To consolidate findings from in vivo and in vitro studies to inform future research directions.
Main Methods
- A systematic literature search was performed across PubMed, Embase, and Web of Science up to March 16, 2024.
- Inclusion criteria focused on English-language in vivo and in vitro studies investigating Tri's effects in AD models.
- Methodological quality of included studies was assessed using SYRCLE and SciRAP tools.
Main Results
- Fifteen studies (6 in vivo, 8 in vitro, 1 combined) met the inclusion criteria from an initial 403.
- Triptolide demonstrated significant reductions in amyloid-beta (Aβ) burden.
- Tri positively impacted memory and synaptic integrity, suppressed neuroinflammation and oxidative stress, and modulated autophagy and apoptosis pathways.
Conclusions
- Triptolide exhibits significant multi-target neuroprotective effects in preclinical models of Alzheimer's disease.
- The findings suggest Tri's potential as a therapeutic agent for AD.
- Further high-quality research is necessary to optimize Triptolide's dosage, delivery methods, and safety profile for clinical application.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...